Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
Research output: Contribution to journal › Article
5-fluorouracil (5FU) and mitomycin C (MMC)-based chemoradiotherapy (CRT) is standard treatment for anal squamous cell carcinoma. In this phase I study cetuximab was added and the primary aim was to determine the maximum tolerated dose (MTD) of 5FU and MMC in this combination.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Journal||European Journal of Cancer|
|Publication status||Published - 2015|